Why the study?
GLP-1 agonists show cardiovascular benefits, but whether they have links in preventing or treating atrial fibrillation remains to be fully examined.
Do GLP-1 agonists prevent or treat atrial fibrillation?
Do GLP-1 agonists prevent or treat atrial fibrillation?
Current evidence on GLP-1 agonists for preventing or treating atrial fibrillation is limited to meta-analyses, highlighting the need for dedicated randomized controlled trials.
Should not yet change AF prevention or treatment; leaves open dedicated RCTs to test any causal GLP-1 agonist effect.
Glucagon-like peptide-1 (GLP-1) agonists, originally developed as a treatment for type 2 diabetes, have been increasingly shown to demonstrate benefits for patients within the realm of cardiovascular disease, such as patients with obesity and congestive heart failure. As rates of patients with these conditions climb, the prevalence of atrial fibrillation, one of the world's most common arrhythmias, has also increased. The goal of this literature review is to examine what, if any, links GLP-1 agonists may have in preventing or treating atrial fibrillation. To date, a number of meta-analyses have been conducted studying potential relationships between GLP-1 agonists and atrial fibrillation, but there has yet to be a randomized controlled trial fully exploring GLP-1's effects on atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Maksymiuk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: